Previous 10 | Next 10 |
home / stock / bovnf / bovnf news
BioInvent strengthens Investor Relations PR Newswire LUND, Sweden, Nov. 27, 2020 LUND, Sweden , Nov. 27, 2020 /PRNewswire/ -- BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-...
BioInvent and Cantargia sign manufacturing agreement for monoclonal antibody CAN10 PR Newswire LUND, Sweden, Nov. 26, 2020 LUND, Sweden , Nov. 26, 2020 /PRNewswire/ -- Cantargia AB (OMXS: CANTA) and BioInvent International AB (OMXS: BINV), today announced tha...
CStone Pharma out-licensed global rights (ex-China) for two immuno-oncology assets to US-based EQRx in a $1.3 billion agreement. CASI Pharma in-licensed China rights to a novel antibody checkpoint receptor inhibitor from Sweden's BioInvent in a $95 million deal. Shanghai's Zai Lab...
BioInvent International (BOVNF): Q3 GAAP EPS of -SEK0.04.Revenue of SEK16.3M (-9.9% Y/Y).Press Release For further details see: BioInvent International reports Q3 results
BioInvent Interim Report January 1 - September 30, 2020 PR Newswire LUND, Sweden, Oct. 29, 2020 LUND, Sweden , Oct. 29, 2020 /PRNewswire/ -- China licensing agreement further validates technology and strategy "The exclusive licensing agreement w...
BioInvent International ([[BOVNF]]) and CASI Pharmaceuticals ([[CASI]] +3.6%) have entered into an exclusive licensing agreement for the development and commercialization of novel anti-FcγRIIB antibody, BI-1206, in mainland China, Taiwan, Hong Kong and Macau.BioInvent wi...
Notice to Extraordinary General Meeting in BioInvent International AB PR Newswire LUND, Sweden, Oct. 27, 2020 LUND, Sweden , Oct. 27, 2020 /PRNewswire/ -- The Board of Directors in BioInvent International AB ("BioInvent" or the "Company") has resolved: ...
Denmark regulators have signed off Phase 1/2a evaluating BioInvent International's ([[BOVNF]]) BI-1808 as a single agent, as well as in combination with Merck's Keytruda, for solid tumors and cutaneous T-cell lymphoma.The 120-subject study will evaluate the safety, to...
LUND, Sweden , Aug. 21, 2020 /PRNewswire/ -- BioInvent International AB (OMXS: BINV) will issue its interim report for the second quarter 2020 on Thursday August 27 at 8.00 a.m. CEST , followed by an audiocast with teleconference at 5.30 p.m. CEST , hosted by Martin Welschof, CEO ...
LUND,Sweden, July 22, 2020 /PRNewswire/ -- . Alexander Eggermont , MD, PhD, Chief Scientific Officer at the Princess Máxima Center and renowned expert in immunotherapy showcased the broad potential of BI-1206 in enhancing checkpoint inhibitors in solid cancers in a KOL event h...
News, Short Squeeze, Breakout and More Instantly...
LUND, SWEDEN / ACCESSWIRE / July 22, 2024 / BioInvent International (STO:BINV) Two posters to be presented on early clinical projects from BioInvent's robust pipeline totaling six clinical programs: Progress with the Phase 1 trial studying BI-1910 as single agent in solid tumors Initial...
LUND, SE / ACCESSWIRE / July 17, 2024 / BioInvent International (STO:BINV) Agreement to support expansion of BI-1607 program with new Phase 2 triplet combination study in metastatic melanoma The study will evaluate anti-FcγRIIB antibody BI-1607 with low-dose anti-CTLA-4, ipilimu...
Model-informed approach supporting dose selection and optimization of clinical development Confirming wide potential dose-range of BI-1808 in the continued clinical evaluation which already has shown promising single agent safety and efficacy Poster to be presented at PAGE 2024 to be ...